Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial
- 21 January 2022
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 163, 152-162
- https://doi.org/10.1016/j.ejca.2021.12.028
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS StudiesClinical Cancer Research, 2014
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with VemurafenibCancer Discovery, 2012
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFRNature, 2012
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation StatusJournal of Clinical Oncology, 2011
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- BRAFMutation in Metastatic Colorectal CancerThe New England Journal of Medicine, 2009
- Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Mutations of the BRAF gene in human cancerNature, 2002
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989